Update on the Diagnosis and Management of Desmoplastic Melanoma

Abstract

Desmoplastic melanoma (DM) accounts for 0.4% to 4% of all melanomas. These skin tumors are mainly formed by amelanotic spindled melanocytes immersed in an abundant collagen stroma and are classified as pure when the desmoplastic component accounts for at least 90% of the invasive tumor and as mixed or combined otherwise. DMs are more common in men (male to female ratio, 1.7 to 2:1), and the mean age at diagnosis is 66 to 69 years. The tumors tend to occur in chronically sun-exposed areas, often in association with lentigo maligna, and are difficult to recognize because they can resemble a scar, presenting as a firm, unpigmented papule or plaque with poorly defined borders. DMs also have a strong tendency to recur locally, and pure variants rarely spread to the lymph nodes. Nonetheless, recently published series suggest that patients with DM have a similar prognosis to those with nondesmoplastic melanoma of the same thickness. The clinical management of DM varies in certain aspects from that of other melanomas and is reviewed in this article.

Keywords: Biopsia selectiva del ganglio centinela; Desmoplastic melanoma; Immunotherapy; Inmunoterapia; Melanoma desmoplásico; Melanoma desmoplásico mixto; Melanoma desmoplásico puro; Mixed desmoplastic melanoma; Prognosis; Pronóstico; Pure desmoplastic melanoma; Sentinel lymph node biopsy.